Coherus Oncology Receives 'Hold' Rating from Analysts

Biotechnology firm's stock faces mixed outlook from research firms

Apr. 7, 2026 at 8:27am

Got story updates? Submit your updates here. ›

An extreme close-up of various metal gears, levers, and mechanical components that make up the inner workings of a complex financial system, conveying a sense of the heavy, tangible nature of the industry.The intricate machinery and infrastructure behind the financial markets represent the institutional power and security that investors rely on, even as individual biotechnology stocks face an uncertain outlook.Redwood City Today

Coherus Oncology, Inc. (NASDAQ:CHRS), a commercial-stage biopharmaceutical company focused on oncology support and immunotherapy, has received an average 'Hold' rating from five research firms currently covering the stock. While one analyst has a 'Sell' rating, three have assigned 'Buy' recommendations and one has a 'Hold' on the company.

Why it matters

Coherus Oncology's mixed analyst ratings reflect the challenges and uncertainties facing the biotechnology industry, particularly around the development and commercialization of new cancer therapies. The company's performance and outlook will be closely watched by investors as it seeks to grow its portfolio of oncology support and immunotherapy products.

The details

The average 12-month price target for Coherus Oncology's stock is $5.51 among the analysts covering the company. Wall Street Zen recently upgraded the stock from 'Sell' to 'Hold', while Oppenheimer initiated coverage with an 'Outperform' rating and $10 price target.

  • Coherus Oncology reported its latest quarterly earnings on March 9, 2026.
  • The company's stock has traded between $0.71 and $2.62 over the past 52 weeks.

The players

Coherus Oncology, Inc.

A commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology.

Wall Street Zen

An equity research firm that recently upgraded Coherus Oncology's stock rating from 'Sell' to 'Hold'.

Oppenheimer

An investment bank that initiated coverage of Coherus Oncology with an 'Outperform' rating and $10 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Coherus Oncology's mixed analyst ratings highlight the challenges facing biotechnology firms as they navigate the complex and competitive oncology market. The company's ability to grow its portfolio of cancer support and immunotherapy products will be a key factor in determining its long-term success.